News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I (World)
Genmab A/S (GEN.CO) Release: Data Published In The New England Journal of Medicine Shows Daratumumab Monotherapy Induced Durable Responses In Heavily Pre-Treated Relapsed Or Refractory Multiple Myeloma Patients 8/27/2015
Portage Biotech's Biohaven Doses First Human Subject In Phase 1 Trial With Lead Drug Candidate BHV-0223 8/27/2015
ORYZON To Present At Rodman & Renshaw 17th Annual Global Investment Conference 8/27/2015
Antibe Therapeutics Inc. (ATE.V) Reports Q1 2016 Interim Financial And Operating Results And A Further Update On Its Validation Studies 8/27/2015
Nordic Nanovector: Results For The Second Quarter And Half Year 2015 8/26/2015
Cardiome Pharma Corp. (COM.TO) Expands Partnership With Eddingpharm (Cayman) Inc. To Commercialize AGGRASTAT In China 8/24/2015
DelMar Pharmaceuticals To Present VAL-083 Lung Cancer Clinical Strategy At The 16th World Conference On Lung Cancer 8/24/2015
NMT Pharmaceuticals Singapore Announces Signing Of Letter Of Intent With CAO Pharmacueticals USA In Licensing And Development Of Anti-Cancer Drug CZ-48 8/24/2015
RedHill Biopharma Ltd. (RDHL) Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of ABC294640 (YELIVA(TM)) In Prostate Cancer 8/24/2015
PharmaMar Announces License Agreement With Specialised Therapeutics Australia Pty For APLIDIN (plitidepsin) In Oncology 8/20/2015
BioLineRx Ltd. Reports Second Quarter 2015 Financial Results 8/20/2015
CytoDyn Release: First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial 8/18/2015
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding From NRC-IRAP To Support Expanded Research Program With Lead Product Candidate VAL-083 8/17/2015
3SBio Inc. (SSRX) Selected As A Constituent Of The Hang Seng Composite LargeCap & MidCap Index 8/17/2015
Hua Medicine’s Diabetes Drug Shows Efficacy In Phase Ic Trial 8/13/2015
Immunovaccine Inc. Announces Financial Results For Quarter Ended June 30, 2015 8/13/2015
BioLineRx Ltd. To Report Second Quarter 2015 Results On August 20, 2015 8/13/2015
Portage Biotech's Biohaven Raises $ 4.1 Million In First Tranche Of Private Placement. Portage Invests $ 2.5 Million 8/11/2015
Intec Pharma Ltd. Announces Closing of U.S. Initial Public Offering 8/10/2015
Regeneus (RGS.AX) (ASX:RGS) First Patient Treated In Progenza Stem Cell Trial For Knee Osteoarthritis 8/10/2015
Antibe Therapeutics Inc. (ATE.V) Announces Completion Of Phase I Studies Of ATB-346 And An Update On Its Validation Studies 8/10/2015
Pharmaxis (PXS.AX) And Synairgen plc Announce Research Collaboration To Develop LOXL2 Inhibitor For Pulmonary Fibrosis 8/5/2015
BeiGene Co.,Ltd Receives Approval To Initiate Clinical Trials In China With BGB-283 For Solid Tumor Cancers 8/3/2015
Suzhou Connect Reports Positive Results For Trial Of Autoimmune Drug 7/30/2015
Kyowa Hakko Kirin And Bristol-Myers Squibb (BMY) Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab And Opdivo (Nivolumab) In Advanced Solid Tumors In The U.S. 7/30/2015
GlaxoSmithKline (GSK) CEO Confident Investors Will Be Pleased With Pipeline on Nov. R&D Day 7/30/2015
Medivir (MVRBF) Announces Start Of A Phase I Clinical Trial Of The Nucleotide Polymerase Inhibitor AL-704 For Treatment Of Hepatitis C 7/29/2015
Cardiome Pharma Corp. (COM.TO) Partner Eddingpharm (Cayman) Inc. To Initiate BRINAVESS Phase I Study In China 7/24/2015
ANGLE plc Preliminary Results For The Year Ended 30 April 2015 7/23/2015
Beike Bio-Technology Co. Ltd Publishes New Research Finding Adult Mesenchymal Stem Cells Safe And Effective In Acute Myocardial Infarction 7/21/2015
MGB Biopharma Limited Commences Phase I Clinical Trial With Oral Formulation Of MGB-BP-3 For The Treatment Of Multi-Resistant Clostridium Difficile Infections 7/21/2015
Peritech Pharma’s Novel Hemorrhoids Treatment Shown Superior To Preparation-H In Pivotal Trial 7/21/2015
OrbusNeich Announces Enrollment Of First Patient In China Recovery Study 7/20/2015
DelMar Pharmaceuticals Expands GBM Clinical Trial With Fifth Clinical Trial Site Added In Denver, Colorado 7/20/2015
THERAVECTYS To Present Detailed Phase I/II Results From The First-Ever Lentiviral-Vector Based Therapeutic Vaccine Trial At The 2015 Towards An HIV Cure Symposium 7/20/2015
InnaVirVax Presents Highly Encouraging Results Of Its First Clinical Study On VAC-3S Immunotherapy For HIV 7/20/2015
BeiGene Co.,Ltd Doses First Patient In Phase Ib Study Of BGB-283, A Novel Second Generation B-RAF Inhibitor 7/14/2015
Adocia Initiates Two Clinical Studies On Its Combination Of Long-Acting Insulin Glargine And Fast-Acting Insulin Lispro, Biochaperone Combo 7/10/2015
BIO2015 EXCLUSIVE: BioSpace (DHX)’s Insider Profile of Neovacs SA 7/9/2015
AXON Neuroscience’s Vaccine To Halt Alzheimer’s Finishes Phase 1 Clinical Trial 7/8/2015
Curetis Initiates Next Phase Of Unyvero U.S. FDA Trial In Lower Respiratory Tract Infections 7/8/2015
Enzymotec Announces Investigator Initiated Clinical Trial Of Vayarin In Managing ADHD In Children With Epilepsy 7/7/2015
PhytoTech Medical Ltd (ASX:PYL) Oral Formulations Advance Towards Phase 1 Clinical Trials 7/6/2015
Avexxin Completes Phase I/IIA Study In Psoriasis And Achieves Proof-Of-Concept In Man With Its Compound AVX001 In A Topical Formulation 7/2/2015
Replicel Life Sciences Enrolls First Participant In Phase 1/2 Clinical Trial Of RCT-01 For Chronic Achilles Tendinosis 6/30/2015
RedHill Biopharma Ltd. (RDHL) Initiates Phase I/II Study Of ABC294640 For Refractory Lymphoma 6/29/2015
Bioiberica To Trial A New Compound On Human Subjects That Prevents Memory Loss In Patients With Mild Alzheimer's 6/29/2015
ProQR Therapeutics B.V. (PRQR) Announces Enrollment Has Started In Global Phase 1b Study Of QR-010 In Cystic Fibrosis Patients 6/26/2015
RestorGenex Announces Prostate Cancer Data On RES-529, A Dual TORC1/TORC2 Inhibitor 6/23/2015
Heptares Announces Positive Outcome Of Phase 1A Study With First-Ever Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Patients With Alzheimer's Disease 6/17/2015
Prothena (PRTA) Presents Clinical Results Demonstrating Robust, Rapid Reduction In Levels Of Free Serum Alpha-Synuclein Of Up To 96% After Single Dose Of PRX002, Novel Protein Immunotherapy For Parkinson's Disease 6/17/2015
Neovacs SA Initiates Clinical Program In Dermatomyositis 6/16/2015
Laurent Pharmaceuticals Announces Positive Phase 1b Topline Results For LAU-7b In Cystic Fibrosis 6/15/2015
Amarillo Biosciences (AMAR) Announces Presentation Of Eltoprazine Phase I/IIa Clinical Data At The 19th International Congress Of Parkinson's Disease And Movement Disorders 6/15/2015
Prothena (PRTA)'s NEOD001 Protein Immunotherapy Clinical Data Highlighted In Oral Presentation At The 20th Congress Of The European Hematology Association 6/12/2015
BerGenBio AS Initiates NSCLC Clinical Trial With BGB324 In Combination With erlotinib 6/10/2015
Prothena (PRTA) Announces First Human Dosed In Phase I Study Of PRX003 For The Treatment Of Psoriasis And Other Inflammatory Diseases 6/10/2015
FDA Awards Isarna Therapeutics Orphan Drug Designation For ISTH0036 To Improve Glaucoma Treatment Outcome 6/10/2015
Merck's KEYTRUDA (pembrolizumab) Receives Conditional Approval In Canada For The Treatment Of Advanced Melanoma 6/8/2015
BeiGene Co.,Ltd Enrolls First Patient In Phase I Study Of BGB-A317, A Humanized Anti-PD-1 Monoclonal Antibody 6/8/2015
Prothena (PRTA) To Present Clinical Results From Its Phase I Single Ascending Dose Study Of PRX002 At 19th International Congress Of Parkinson's Disease And Movement Disorders 6/8/2015
ASCO15: Prothena (PRTA) Presents Compelling New Data From Ongoing Phase I/II Study Of NEOD001 In Patients With AL Amyloidosis At 2015 ASCO Annual Meeting 6/2/2015
Aptose Biosciences Granted Orphan Drug Designation By The U.S. FDA For APTO-253 In Acute Myeloid Leukemia 6/2/2015
ASCO15: Adaptimmune Announces Data From Clinical Studies Of NY-ESO-1 Specific T-Cells In Multiple Cancers At The 2015 Annual ASCO Meeting 6/1/2015
ASCO15: VBL Therapeutics (VBLX) To Present Phase I/IIa Data From VB-111 In Recurrent Platinum-Resistant Mullerian Cancer At The 2015 ASCO Annual Meeting 6/1/2015
BerGenBio AS Release: BGB324 And BGB10C9 Show Promise In Models Of Pancreatic Cancer 6/1/2015
ASCO15: Targovax Releases TGO1 RAS-Mutation-Specific Immunotherapy Data At ASCO 6/1/2015
ASCO15: Hanmi Pharma ‘HM61713’ Demonstrated The Effect Of Tumor Volume Reduction 6/1/2015
Synageva BioPharma (GEVA) Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Japan 5/27/2015
Alizé Pharma Presents Clinical Results From The AZP-531 Program At The American Diabetes Association 75th Scientific Sessions 5/26/2015
R-Tech Ueno: Announcement On Completion Of The Phase I Single-Dose Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096 5/26/2015
e-Therapeutics plc Release: Progress In ETS2101 Phase Ib Study 5/21/2015
Isarna Therapeutics Announces Orphan Drug Designation In The European Union For ISTH0036 To Treat Advanced-Stage Glaucoma 5/21/2015
Prothena (PRTA) Announces Presentation Of Clinical Data From The Ongoing Phase I/II NEOD001 Study And Systemic Amyloidosis Patient Survey Results At 20th Congress Of The European Hematology Association 5/21/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Phase 1 Study In Pediatric Patients With Brain Tumors 5/19/2015
Significant Progress For Pluristem Therapeutics (PSTI): PLX Cells Were Selected For European Medicines Agency's Adaptive Pathways Pilot Project 5/18/2015
TopiVert Starts Phase I Clinical Trial In Ulcerative Colitis 5/14/2015
Oxford University, GlaxoSmithKline (GSK) And Emergent BioSolutions (EBS) Announce Initiation Of A Prime Boost Study Of Ebola Vaccine Candidates 5/13/2015
Bavarian Nordic (BAVA.CO) Announces Presentation Of Preliminary Phase 1 Results For The Ebola Prime-Boost Vaccine Regimen Of MVA-BN Filo And Janssen Pharmaceutical's AdVac Technology 5/13/2015
Drawbridge Pharmaceuticals Moves Phaxan Forward 5/4/2015
Basilea Pharmaceutica (BSLN.SW) Reports Start Of First-In-Human Phase I Oncology Study With Oral Panraf Kinase Inhibitor 5/4/2015
Ascendis Pharma A/S Announces Results Of Phase 1 Study Of Transcon Treprostinil 4/29/2015
GW Pharmaceuticals (GWPH) Receives Orphan Drug Designation From FDA For Cannabidiol For The Treatment Of Neonatal Hypoxic-Ischemic Encephalopathy 4/24/2015
Nordic Nanovector: Results Of Phase 1 Study Of Betalutin In Patients With Non-Hodgkin Lymphoma To Be Presented At The International Conference On Malignant Lymphoma 4/23/2015
Cardio3 Biosciences Announces Infusion Of First Patient In NKG2D Phase I Trial With No Short Term Adverse Events 4/20/2015
AstraZeneca PLC (AZN)'s Experimental Lung Cancer Drug Delays Disease By More Than a Year 4/20/2015
cCam Biotherapeutics Announces Initiation Of Phase 1 Trial Of CM-24, A Novel Immune Checkpoint Inhibitor For Cancer Immunotherapy 4/20/2015
OncoMed Pharmaceuticals, Inc. (OMED) Presents Demcizumab Data From Phase 1b Clinical Trial In Non-Small Cell Lung Cancer Patients At The European Lung Cancer Conference 4/16/2015
Isarna Therapeutics Initiates First-In-Human Phase I Trial For ISTH0036 To Treat Advanced Glaucoma 4/16/2015
Suven Life Sciences Ltd Initiated Multiple Ascending Dose (MAD) Studies In Phase 1 Clinical Trial For Their Investigational Compound SUVN-G3031 4/13/2015
Sihuan Pharmaceutical Starts US Trial Of Novel Cancer Drug 4/10/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
Luye Pharma Reports Successful Phase I Trials Of Novel Anti-depressant 4/2/2015
ESSA Pharma Announces Filing Of Investigational New Drug Application For EPI-506 4/1/2015
Portage Biotech's Biohaven Announces Agreement With inVentiv Health (VTIV) 4/1/2015
PledPharma Presents Top-Line Results From Its PhaseIIb Study - Pledox(R) Reduces Nerve Damage In Conjunction With Chemotherapy By 43 Percent 3/30/2015
IntelliPharmaCeutics Reports Positive Topline Data Results From A Series Of Phase I Clinical Trials Of Its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, And Files An IND For Rexista(TM) Oxycodone XR 3/30/2015
Tianjin CanSino Biotechnology Release: China Ebola Vaccine Passes Phase I Test 3/26/2015
MorphoSys AG And Celgene (CELG) Mutually Agree To End MOR202 Collaboration 3/26/2015
Cellular Biomedicine Group (CBMG) Announces Phase I Results From CAR-T Immuno-Oncology Clinical Development Programs 3/25/2015
BioLineRx Ltd. Reports Successful Top-Line Safety And Efficacy Results For Novel Stem Cell Mobilization Treatment 3/25/2015
Relmada Therapeutics Receives Health Canada Clearance To Commence First Clinical Study For Novel Oral Formulations Of Buprenorphine 3/24/2015
Prothena (PRTA) Soars on Positive Phase I Results Of Parkinson's Drug PRX002 3/24/2015
Another Day, Another $456 Million Cancer Pact for Eli Lilly (LLY) 3/23/2015
AB Science (AB.PA): Masitinib Receives Orphan Drug Designation For Amyotrophic Lateral Sclerosis From FDA 3/23/2015
Kamada Ltd. (KMDA) Awarded European Orphan Drug Designation For Its Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease 3/23/2015
HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan 3/19/2015
Zai Lab Begins Trial Of Novel Respiratory Disease Drug 3/17/2015
VAXIL Receives EU Orphan Drug Designation For Immucin For The Treatment Of Multiple Myeloma 3/16/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
ASLAN Reports Positive Phase I Results From Cancer Drug 3/16/2015
Dr. Falk Pharma And Zedira Enter Phase I Clinical Trials For A Celiac Disease Drug 3/13/2015
Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of Its Novel Anemia Therapeutic TBI 304H 3/12/2015
Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial 3/11/2015
MorEx Moves To Intent-to-Cure Stage Of MTL-005 Radiation Enhancer Head & Neck Cancer Phase 1 Trial 3/11/2015
Innate Pharma (IPH.PA ) Collaborates With NCIC Clinical Trials Group On The Phase I/II Trial Of IPH2201 In Ovarian Cancer 3/9/2015
ORYX Successfully Completes Phase 1/2a Trial With Therapeutic Vaccine Vicoryx To Treat HPV-Associated Cancers 3/9/2015
Targovax To Expand On-Going Phase I/II CT-TG01-01 Pancreatic Cancer Study With A New Group Of Up To 13 Patients 3/9/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Primary Peritoneal Cancer 3/3/2015
Almac Discovery Initiates Phase 1 Study Of ALM201 For The Treatment Of Patients With Advanced Ovarian Cancer And Other Solid Tumours 3/2/2015
Bavarian Nordic (BAVA.CO) Announces Updated Overall Survival Data From Combination Immunotherapy Data Of PROSTVAC Plus Ipilimumab At The 2015 Genitourinary Cancers Symposium 2/24/2015
Galapagos NV (GLPG.BR) Reports Positive Phase 1 Results For GLPG1690 2/16/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Ovarian Cancer 2/11/2015
BIOCEO15: BioLineRx Ltd. CEO Touts New Celiac Drug, Fleshes Out Novartis AG (NVS) Partnership Terms 2/11/2015
Akaal Pharma Announces Positive Results From Phase 1 Clinical Study Of Novel Topical AKP-11 For The Treatment Of Psoriasis 2/5/2015
Pluristem Therapeutics (PSTI) Announces Significant New Finding From Its Phase I/II Muscle Injury Trial And Excellent Safety Profile For PLX-PAD Cells At Twelve Months 2/2/2015
Protalix Biotherapeutics, Inc. (PLX) Completes Enrollment In Phase I/II Clinical Trial Of PRX-102 For Fabry Disease 2/2/2015
First Trial Finds GlaxoSmithKline (GSK) Ebola Shot Safe 1/29/2015
Adocia Initiates A Clinical Study On The Post-Meal Effect Of Ultra-Rapid Biochaperone Lispro Insulin Formulation 1/21/2015
Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial 1/19/2015
Newron Pharmaceuticals (NWRN) Announces Results Of Phase I Study Of NW-3509 Phase II Study In Schizophrenia Patients Planned For Q2 2015 1/15/2015
Aptose Biosciences Doses First Patient In Phase 1b Clinical Study Of APTO-253 In Relapsed Or Refractory Hematological Malignancies 1/14/2015
PsiOxus Therapeutics Limited Release: European Medicines Agency Grants Positive Opinion For Orphan Drug Status For Ovarian Cancer Oncolytic Vaccine 1/13/2015
DelMar Pharmaceuticals Provides Update On VAL-083 Clinical Trial And Outlines Corporate Objectives For 2015 1/12/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Receives Clearance From Health Canada For Diabetes Clinical Trial 1/8/2015
Targovax Reports Completion Of Recruitment Of Patients In The Phase 1/2 Clinical Trial CT TG01-01 1/8/2015
Benitec, Inc. (BLT.AX) Advances Hepatitis C Clinical Trial 1/7/2015
BioLineRx Ltd. Completes Dose Escalation Stage Of Phase 1 Trial For Novel Stem Cell Mobilization Treatment 1/6/2015
Gamida Cell Ltd.'s NiCord® Receives FDA And European Medicines Agency Orphan Drug Designation 1/6/2015
Merck & Co. (MRK), NewLink Genetics Ebola Vaccine Trial Resumes in Geneva 1/5/2015
AEterna Zentaris (AEZS): Final Data For Phase 1 Portion Of Ongoing Phase 1/2 Trial With Zoptarelin Doxorubicin In Prostate Cancer Published In Clinical Cancer Research 12/29/2014
Novastem Treats First Patient Using Stemedica Cell Technologies, Inc.'s Mesenchymal And Neural Stem Cell Combination Therapy For Ischemic Stroke 12/24/2014
New Published Data Show Pluristem Therapeutics (PSTI)'s PLX Cells Protect Neurons 12/22/2014
e-Therapeutics plc Reports Progress In ETS2101 Phase 1a And Oral Dosing Studies 12/18/2014
TiGenix Starts Phase I Trial Of Cx611 In Severe Sepsis 12/10/2014
MorphoSys AG And Xencor Publish Final Results From Phase 1/2a Trial Of MOR208 (Xmab5574) In CLL/SLL At Xencor Annual Meeting 12/8/2014
Nordic Nanovector Presented Phase I Study Data Reporting Promising Clinical Activity In Patients With Relapsed Non-Hodgkin Lymphoma At American Society of Hematology 12/8/2014
VAXIMM Reports Positive Follow-On Data From Oral Cancer Vaccine Trial 12/4/2014
Bavarian Nordic (BAVA.CO) Announces First Subject Dosed With Mva-Bn Filo In A Phase 1 Study Investigating A New Prime-Boost Regimen Of Ebola Candidate Vaccines 12/4/2014
Rhizen Pharmaceuticals S.A. To Present Phase 1 Clinical And Additional Preclinical Data Of RP6530 (Dual PI3K Delta/Gamma Inhibitor) In Hematological Malignancies 12/3/2014
CollPlant Launched A Clinical Trial With VergenixFG; A Gel Based On A Human Collagen For The Treatment Of Chronic Wounds 12/2/2014
AstraZeneca PLC (AZN) And Eli Lilly (LLY) Move Alzheimer's Drug Into Big Trial 12/1/2014
Dynavax Technologies Corporation (DVAX) Regains Full Rights To Investigational TLR 7/9 Inhibitor DV1179 Following Expiration Of Collaboration With GlaxoSmithKline (GSK) 12/1/2014
Karyopharm Therapeutics (KPTI) Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission (EC) 12/1/2014
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
ABIVAX Successfully Completes First-In-Man Study Of ABX464, A Highly Differentiated Small Molecule Targeting HIV 12/1/2014
GlaxoSmithKline (GSK), NIH Report Positive Ebola Vaccine Phase 1 Trial 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 11/26/2014
Synthon Initiates Treatment Of First Patients In Phase I Trial Of Anti-HER2 ADC SYD985 Based On Its Proprietary Linker-Drug Platform 11/25/2014
$1 Billion Oncology Alliance Between Menarini Group & Oxford BioTherapeutics Initiates First-In-Human Study Of Enhanced Antibody For Treatment Of Acute Myeloid Leukemia 11/25/2014
Transition Therapeutics Inc. (TTH.TO)' ELND005 Showed No Prolongation Of QT Interval 11/24/2014
Admedus HPV Vaccine Heads To The Clinic 11/24/2014
OncoMed Pharmaceuticals, Inc. (OMED) Presents New Clinical And Biomarker Data From Its Tarextumab And Demcizumab Clinical Trials At The European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium 11/24/2014
Transition Therapeutics Inc. (TTH.TO) Announces Results From ELND005 Clinical Study In Adults With Down Syndrome 11/20/2014
Themis Bioscience’s Vaccine Against Chikungunya Successful In Phase 1 11/20/2014
BerGenBio AS Receives Orphan-Drug Designation From FDA For BGB324 In The Treatment Of Acute Myeloid Leukaemia 11/19/2014
Clovis Oncology (CLVS) Release: Interim Data From Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling And Durable Clinical Activity And Progression-Free Survival (PFS) In Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) 11/19/2014
3-V Biosciences Announces Presentation Of First Human Clinical Data For Lead Oral FASN Inhibitor Candidate At European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research 2014 11/19/2014
The Lancet Neurology Publishes Prana’s Huntington Disease Trial 11/18/2014
Agios Pharmaceuticals (AGIO) Announces Early Phase 1 Data Showing Clinical Activity Of AG-120 As A Single Agent In Advanced Acute Myeloid Leukemia (AML) 11/18/2014
Canadian Institutes Of Health Research Release: Canada Begins Ebola Vaccine Trial 11/14/2014
Cell Source's Megadose Drug Combination Receives Regulatory Approval In Italy To Commence Human Clinical Trials 11/13/2014
Oncoethix Starts Phase 1b Trials Of OTX015 In The Treatment Of Advanced Solid Tumors (OTX015_107) And Glioma (OTX015_108) 11/12/2014
R-Tech Ueno: Completion Of A Phase I/II Clinical Study Of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) In The U.S. For The Treatment Of Severe Dry Eye 11/10/2014
BioLineRx Ltd. Announces Successful Final Results Of Phase 1/2 Study For Novel Celiac Treatment 11/5/2014
BerGenBio AS Announces First Patient Dosed in BGB324 AML Trial 11/4/2014
MorEx Extends Phase I MTL-005 Radiation Enhancer Head & Neck Cancer Trial 11/3/2014
Suven Life Sciences Ltd Release: SUVN-G3031 For Cognition In Alzheimer’s Disease Commenced Phase 1 Clinical Trial In U.S.A. Under US-IND 123179 11/3/2014
Kiadis Pharma's Lead Product ATIR™ Granted Orphan Drug Designation By European Medicines Agency For The Treatment Of Acute Myeloid Leukemia 10/30/2014
Osteros Biomedica Announce Initiation Of A Phase I Clinical Trial 10/28/2014
TxCell Achieves Positive Results For Col-Treg In A Model Of Autoimmune Uveitis 10/28/2014
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/28/2014
uniQure Release: AIPGENE Consortium Presents 1 Year Follow-Up Clinical Data From Acute Intermittent Porphyria Phase I Clinical Trial Using AAV5-PBGD Gene Therapy Candidate 10/27/2014
Trinity Biotech (TRIB) Temporary Suspends Meritas Troponin Trials 10/23/2014
Novartis AG (NVS)'s Leukemia Drug CTL01 Clears Cancer In 90 Percent Of Patients 10/20/2014
MediGene, Inc. Announces Publication In Cancer Immunology, Immunotherapy On DC Vaccine Development For A Phase 1/2 Trial In Acute Myeloid Leukemia 10/16/2014
ActoGeniX Announces Positive Results From A Phase 1 Study Of AG014; Oral Capsule Administration Of An Anti-TNF-Alpha Antibody For The Treatment Of Inflammatory Bowel Disease 10/15/2014
Scancell Release: AGM Research And Development Update Highlights Progress In Both SCIB1 Clinical Trial And Moditope® Platform 10/14/2014
EU-Funded Consortium Led By immatics biotechnologies GmbH And BioNTech To Advance A Novel Class Of Fully Personalized Therapeutic Cancer Vaccines Into Clinical Trials For Brain Cancer 10/14/2014
Mali Health Workers Get Experimental GlaxoSmithKline (GSK) Ebola Vaccine 10/13/2014
Public Health Agency of Canada Release: Canadian Ebola Vaccine Trials Begin 10/13/2014
PharmaEngine, Inc. Will Join Nanobiotix' Pivotal Trial For NBTXR3 In Soft Tissue Sarcoma To Accelerate Its Development In Asia-Pacific 10/8/2014
Debiopharm Group™ Announces Progress In Phase I Single And Multiple Ascending Dose Study Of Debio 1450, Its Potent Anti-Staphylococcal Agent 10/7/2014
Novaliq GmbH Reports Positive Results From Cyclasol® (Cyclosporin Solution) Eye Drops Repeated And Ascending Dose Phase 1 Study 9/23/2014
First European Patients Enrolled In QT QT Vascular's ENDURE Trial 9/16/2014
United Therapeutics Corporation (UTHR) Advances To Second Cohort In Phase I Trial Of Pluristem Therapeutics (PSTI)'s PLX-PAD Cells For Treatment Of Pulmonary Arterial Hypertension 9/8/2014



//-->